Allena Pharmaceuticals Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.(i)
  • Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
  • Allena Pharmaceuticals's estimated revenue per employee is $335,833
  • Allena Pharmaceuticals's total funding is $2.9B.
  • Allena Pharmaceuticals's current valuation is $37.1M. (January 2022)

Employee Data

  • Allena Pharmaceuticals has 18 Employees.(i)
  • Allena Pharmaceuticals grew their employee count by -60% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.

keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Allena Pharmaceuticals's People

SVP, Technical Operations
CMC Project Manager
Senior Accountant
Chief Financial Officer
VP, Finance
Director, Quality Assurance

Allena Pharmaceuticals News

2022-04-17 - Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Expected to ...

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme...

2022-04-17 - Reviewing Renovacor (NYSE:RCOR) and Allena ...

Get Allena Pharmaceuticals alerts: This table compares Allena Pharmaceuticals and Renovacor's revenue, earnings per share (EPS) and valuation.

2022-04-17 - Allena Pharmaceuticals (NASDAQ:ALNA) vs. Inhibikase ...

Allena Pharmaceuticals (NASDAQ:ALNA) vs. Inhibikase Therapeutics (NYSE:IKT) Head to Head Review. Posted by admin on Apr 15th, 2022.

2021-03-09 - ALLENA PHARMACEUTICALS, INC. Allena Pharmaceuticals : Corporate Presentation March 2021

Company Presentation March 2021 Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "inten ...

2019-09-08 - -$0.48 EPS Expected for Allena Pharmaceuticals Inc (NASDAQ:ALNA) This Quarter

Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Allena Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-11-17$15.0MABessemer Venture Partners, Frazier HealthcareArticle
2014-12-05$25.0MBHBM PartnersArticle